Prescient Therapeutics Limited

Section 1: Company Overview and Fundamentals

1.1 Company Overview:

Prescient Therapeutics Limited (ASX: PTX) is into biotechnology & medical research, where it focuses on developing personalized medicine approaches for cancer, including cellular and targeted therapies. The company's product pipeline includes OmniCAR, PTX-100, and PTX-200.

1.2 The Key Positives, Negatives, Investment Highlights, and Risks

 1.3 Top 10 Shareholders: The top 10 shareholders together form ~11.75% of the total shareholding. Kenley (David) and Ferris (Christopher) hold a maximum stake in the Company at ~2.86% and ~1.53%, respectively.

1.4 Key Metrics: During FY22, the company recorded other income of AUD 1.89mn compared to AUD 1.23mn in FY21. Below captured the trend of total assets and Government grants:

Section 2: Business Updates, Financial and Operational Highlights

2.1 Recent Updates:

2.2 Insights of FY22: During FY22, the research and development costs have increased to AUD 3.40mn relative to AUD 2.49mn in FY21. The company is targeting to fund the ongoing clinical development of its therapies PTX-100 and PTX-200 and expects to raise AUD 8.0mn through Share Purchase Plan.

2.3 Future Developments: The company works on important clinical programs in Australia and USA for the targeted cancer therapeutics PTX-100 & PTX-200 and achieved clinical milestones in FY22. The PTX-100 Phase 1b basket trial showed encouraging results during FY22, while the ongoing Phase 1b trial of PTX-200 advanced to higher dose levels after the trials revealed better safety and efficacy data at lower dose levels.

Section 3: Key Risks and Outlook:

Section 4: Stock Recommendation Summary:

4.1 Price Performance and Technical Summary:

4.2 Stock Summary

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 24 August 2022. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above. 

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock. 

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.

Note: Prescient Therapeutics Limited (Company) is a client of Kalkine Media Pty Ltd (Kalkine Media), an affiliate of Kalkine. However, under no circumstances have Kalkine or its related entities been, directly or indirectly influenced in making any related insights concerning Company as contained in this report, and no form of compensation is or will be received by Kalkine, Kalkine Media or Kalkine’s other related entities for the publication of this report.

Disclaimer

Kalkine New Zealand Limited is authorised to provide general advice only. The information on this website does not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions.